In last trading session, Rigel Pharmaceuticals (NASDAQ:RIGL) saw 0.41 million shares changing hands with its beta currently measuring 1.31. Company’s recent per share price level of $17.09 trading at -$0.12 or -0.70% at ring of the bell on the day assigns it a market valuation of $301.04M. That closing price of RIGL’s stock is at a discount of -74.49% from its 52-week high price of $29.82 and is indicating a premium of 56.23% from its 52-week low price of $7.48. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.21 million shares which gives us an average trading volume of 226.36K if we extend that period to 3-months.
For Rigel Pharmaceuticals (RIGL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.33. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0.33 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Rigel Pharmaceuticals (NASDAQ:RIGL) trade information
Upright in the red during last session for losing -0.70%, in the last five days RIGL remained trading in the red while hitting it’s week-highest on Monday, 12/16/24 when the stock touched $17.09 price level, adding 13.69% to its value on the day. Rigel Pharmaceuticals’s shares saw a change of 17.86% in year-to-date performance and have moved -9.62% in past 5-day. Rigel Pharmaceuticals (NASDAQ:RIGL) showed a performance of -29.70% in past 30-days. Number of shares sold short was 0.47 million shares which calculate 1.69 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 1.5 to the stock, which implies a fall of -1039.33% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 2. It follows that stock’s current price would jump 94.15% in reaching the projected high whereas dropping to the targeted low would mean a gain of 94.15% for stock’s current value.
Rigel Pharmaceuticals (RIGL) estimates and forecasts
Statistics highlight that Rigel Pharmaceuticals is scoring comparatively higher than the scores of other players of the relevant industry. The company added 78.73% of value to its shares in past 6 months, showing an annual growth rate of 112.14% while that of industry is 16.40. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 44.68% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 47.42M for the same. And 2 analysts are in estimates of company making revenue of 43.49M in the next quarter. Company posted 35.79M and 29.53M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 19.96% during past 5 years.
Rigel Pharmaceuticals (NASDAQ:RIGL)’s Major holders
Insiders are in possession of 2.18% of company’s total shares while institution are holding 68.01 percent of that, with stock having share float percentage of 69.53%. Investors also watch the number of corporate investors in a company very closely, which is 68.01% institutions for Rigel Pharmaceuticals that are currently holding shares of the company. BARCLAYS PLC is the top institutional holder at RIGL for having 10573.0 shares of worth $88000.0. And as of 2024-06-30, it was holding 0.006 of the company’s outstanding shares.
The second largest institutional holder is IFP ADVISORS, INC, which was holding about 1000.0 shares on 2024-06-30. The number of shares represents firm’s hold over 0.0006 of outstanding shares, having a total worth of $807.0.
On the other hand, Invesco ETF Tr II-Invesco Dorsey Wright SmallCap Momentum ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.04 shares of worth $17.82 million or 5.92% of the total outstanding shares. The later fund manager was in possession of 548.78 shares on Sep 30, 2024 , making its stake of worth around $9.38 million in the company or a holder of 3.12% of company’s stock.
